Protagonist Therapeutics Inc
NASDAQ:PTGX
| Market Cap (Intraday) | 1.47B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $29.27 |
| 50-Day MA | $34.70 |
| 200-Day MA | $33.46 |
Protagonist Therapeutics Inc Stock, NASDAQ:PTGX
7707 Gateway Boulevard, Suite 140, Newark, California 94560-1160
Phone: +1.510.474.0170
Number of Employees: 79
Description
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.